This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adams, L. B.
Right arrow Articles by Krahenbuhl, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adams, L. B.
Right arrow Articles by Krahenbuhl, J. L.

 Previous Article  |  Next Article 

Infection and Immunity, September 2000, p. 5462-5465, Vol. 68, No. 9
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Role of Inducible Nitric Oxide Synthase in Resistance to Mycobacterium leprae in Mice

Linda B. Adams,1,* Charles K. Job,2 and James L. Krahenbuhl1

National Hansen's Disease Programs, Laboratory Research Branch at Louisiana State University, Baton Rouge, Louisiana,1 and St. Thomas Hospital and Leprosy Centre, Chettupattu TS Dt 606 801 Tamil Nadu, South India2

Received 2 December 1999/Returned for modification 14 February 2000/Accepted 5 June 2000


    ABSTRACT
Top
Abstract
Text
References

The manifestation of leprosy in humans is largely determined by host immunity to Mycobacterium leprae and is a model for immunoregulation in a human disease. However, animal models available for exploration of the leprosy spectrum are inadequate. This study explored M. leprae infection in mice deficient in inducible nitric oxide synthase, and this report describes elements resembling borderline tuberculoid leprosy in humans.


    TEXT
Top
Abstract
Text
References

A major component of the antimicrobial repertoire of effector mechanisms of activated macrophages (MPhi ) is the production of reactive nitrogen intermediates (RNI), chiefly nitric oxide, generated from L-arginine by a high-output, cytokine-inducible isoform of the enzyme, inducible nitric oxide synthase (iNOS). In murine models, RNI have been shown to be necessary for the MPhi -mediated inhibition of tumor cells and a variety of extracellular and intracellular pathogens (6, 17). Evidence that RNI play a key antimicrobial role in human MPhi is less direct but is accumulating (21).

The use of the competitive inhibitor of L-arginine, NG-monomethyl-L-arginine (L-NMA), as well as other inhibitors of iNOS, including aminoguanidine (AG), allowed in vitro demonstration that MPhi RNI are important in the gamma interferon (IFN-gamma )-activated MPhi killing of Mycobacterium leprae (2) and M. tuberculosis (1, 8, 11). The inclusion of L-NMA or AG in drinking water permitted in vivo demonstration of the role of RNI in host resistance to M. bovis BCG (15) and M. tuberculosis (7, 13), respectively. Recently, gene knockout (KO) mice with a targeted disruption in the calmodulin binding site of the iNOS gene (iNOS KO mice) were developed which lack a functional iNOS (16). These iNOS KO mice yielded IFN-gamma -treated MPhi incapable of coping with M. tuberculosis (1). In vivo infection with virulent M. tuberculosis was greatly exacerbated in this and another strain of iNOS-deficient mice (1, 18).

The present studies employed iNOS KO mice to explore further the role of RNI in host resistance to viable M. leprae freshly harvested from infected nu/nu mice (3). Figure 1 shows in vitro results obtained with B6 and iNOS KO peritoneal MPhi where additional controls consisted of B6 MPhi treated with the RNI inhibitors L-NMA and AG. Clearly, activated iNOS KO MPhi or B6 MPhi treated with L-NMA or AG failed to produce RNI and were unable to kill or inhibit M. leprae. Similar results were obtained with bone marrow-derived MPhi (not shown).


View larger version (28K):
[in this window]
[in a new window]
 
FIG. 1.   Effects of activated peritoneal MPhi from B6 and iNOS KO mice on M. leprae. (A) Viability of M. leprae recovered from control (open bars) or IFN-plus-lipopolysaccharide-activated (hatched bars) B6 MPhi incubated in the presence or absence of 500 µM AG or 500 µM L-NMA and from iNOS KO MPhi . Viability of bacilli was determined 48 h postinfection by radiorespirometric measurement of the oxidation of [14C]palmitic acid (19). (B) Nitrite levels in the culture supernatants were determined using the Griess reagent. Control versus activated MPhi : **, P < 0.01; ***, P < 0.001.

Dietary inhibition of RNI production was not a feasible approach by which to study the role of this antimicrobial mechanism of resistance to leprosy in vivo because the protracted nature of the mouse footpad model for infection with M. leprae requires several months to demonstrate growth. Therefore, M. leprae infection was carried out with iNOS KO mice to determine if, as in the M. tuberculosis model, MPhi inability to cope with M. leprae infection in vitro is also manifested in vivo by exacerbated infection. We employed the standard Shepard mouse footpad assay (20), in which the number of acid-fast bacilli (AFB) peaks at 4 to 6 months, plateaus for several months, and then gradually falls off to the counting threshold. As shown in Fig. 2, M. leprae growth followed this typical pattern in control B6 mice over 18 months. In iNOS KO mice, counts of AFB per footpad were generally higher at 3 and 6 months in one experiment and 11 months in a second experiment although statistical significance (Welch's t test) was reached only at the 3-month time point (P < 0.05). More noteworthy, considering the marked differences in granuloma formation and histopathological responses (see below), were the findings that the number of AFB per footpad fell off at the same rate and to the same level in KO mice as in controls.


View larger version (15K):
[in this window]
[in a new window]
 
FIG. 2.   Growth of M. leprae in mouse in footpads. B6 (circles) and iNOS KO (triangles) mice were infected in both hind footpads with 104 viable, nu/nu mouse-derived M. leprae organisms. At the indicated times postinfection, the number of AFB per footpad was determined. Open and closed symbols represent two independent experiments. Each symbol represents one mouse, except at the 4- and 6-month time points, where each symbol represents a pool of two mice. The threshold of counting ability (dotted line) is 3 × 103 AFB per footpad.

Clearly, growth of M. leprae was not greatly exacerbated in iNOS KO mice. These results appear to contrast with findings obtained with experimental M. tuberculosis infections, in which the absence of RNI was linked with the inability of activated MPhi to kill in vitro coupled with exacerbated growth of the tubercle bacillus and increased mouse mortality (1, 7, 8, 13, 18). Our findings also contrast with reports in which iNOS-deficient mice not only controlled M. avium growth in vivo but also did so in vitro in activated MPhi (4, 5, 12, 14). Thus, although the present studies appear to underscore the important role of RNI in MPhi -mediated resistance to M. leprae, these findings also demonstrate that control of M. leprae infection in vivo can be maintained in the absence of this potent antimicrobial mechanism. An important alternative antimicrobial pathway to be considered is the production of reactive oxygen intermediates (ROI) by MPhi . We have shown, however, that MPhi from iNOS KO mice are not deficient in the production of ROI (1) but, in the absence of RNI, ROI alone is not sufficient to kill either M. tuberculosis or M. leprae.

Control of M. leprae growth in iNOS-deficient mice may involve a more complicated compensatory consequence of the microenvironmental conditions associated with granuloma formation. At 15 months in B6 mice, the granuloma which formed around an injected bolus of M. leprae was confined to a small area in the footpad immediately underneath the epidermis (Fig. 3A) and consisted of small focal collections of MPhi , a few epithelioid cells, and lymphocytes which were collected around neurovascular bundles. The inflammation did not invade nerves or muscles. There were minimal superficial extensions along the tissue spaces between muscle bundles. Acid-fast staining (not shown) revealed a few clumps of bacilli inside MPhi , especially in those found immediately beneath the epidermis. In marked contrast, the granulomatous inflammation of the iNOS KO footpad was over 10 times the size of the granuloma found in the control mice (Fig. 3B). The granuloma was distributed over an area underneath the epidermis, around neurovascular bundles, and was spread along the tissue spaces between muscle bundles, even reaching the bones. The granuloma was confluent and organized and was composed of numerous epithelioid cells, a few MPhi , and dense collections of lymphocytes (Fig. 3C). In areas, the granuloma infiltrated the muscle bundles, partly destroying them (Fig. 3D), and also infiltrated the perineurium. Acid-fast staining (not shown) revealed clumps of bacilli inside MPhi mainly in the middle of the granuloma. Thus, granuloma formation in iNOS KO mice was ultimately associated with destruction of M. leprae and persisting organisms continued to evoke a granulomatous response. Two recent studies (12, 14) have shown enhanced granuloma formation in M. avium-infected mice when production of RNI was inhibited by either gene disruption or chemical inhibition, and this response was attributed to modulation of cytokine production. Ongoing immunohistopathological studies and evaluation of local cytokine profiles in our M. leprae-infected mouse footpad model may shed further light on these compensatory mechanisms of resistance.


View larger version (136K):
[in this window]
[in a new window]
 
FIG. 3.   Granulomatous response in mouse footpads in response to infection with 104 M. leprae organisms. (A) Small granuloma around a neurovascular bundle in a B6 mouse at 15 months postinfection. It is composed primarily of spindle-shaped MPhi and a few lymphocytes (hematoxylin-and-eosin staining; bar, 100 µm). (B) The granuloma in an iNOS KO mouse at 15 months postinfection was over 10 times the size of that seen in B6 mice and was composed of epithelioid cells and numerous lymphocytes (hematoxylin-and-eosin staining; bar, 100 µm). (C) Higher-power view of the granuloma in iNOS KO mice to show the epithelioid cells with abundant cytoplasm bordered by a dense collection of lymphocytes (hematoxylin-and-eosin staining; bar, 50 µm). (D) The granuloma in iNOS KO mice infiltrated the striated muscles and partly destroyed them (hematoxylin-and-eosin staining; bar, 50 µm).

Finally, it is noteworthy that our findings appear to share attributes with an important form of human leprosy. Overall, the histological picture seen in iNOS KO mice was one resembling human borderline tuberculoid leprosy. The broad clinical-immunopathological spectrum of leprosy represents a fascinating example of immunoregulation in a chronic, nonfatal human infectious disease. But current murine models of experimental leprosy generally represent only the polar forms of the disease: tuberculoid leprosy with limited growth in the footpads of conventional, immunocompetent mice and lepromatous leprosy in which growth is largely unrestricted in the footpads of athymic nu/nu mice (9, 10). The borderline area of the clinical-immunopathological manifestations of leprosy is by far the most intriguing to immunologists. Unlike the tuberculoid and lepromatous forms, the borderline form is unstable and may downgrade and evolve into a more lepromatous disease or upgrade into a more tuberculoid disease, often with the appearance of a "reversal reaction" resulting from the onset of enhanced cell-mediated immunity with damaging consequences for surrounding nerves.

In humans, understanding the mechanisms and prevention of reversal reactions is one of the main goals of leprosy research. The development of strains of mice with targeted gene disruptions has opened up the possibility of exploring models more representative of the human leprosy spectrum. As the M. leprae-infected footpad lesions of iNOS KO mice appear to resemble borderline tuberculoid lesions, the present findings may be exploitable as a model for understanding the instability of borderline disease. Experiments are under way to determine the host response to larger numbers of M. leprae organisms and explore the possibility of further manipulation of the cell-mediated immune system in infected iNOS KO mice.


    ACKNOWLEDGMENTS

We thank Nashone Soileau, J. P. Pasqua, Julie Loesch, Angelina Deming, and Greg McCormick for technical assistance and Penne Cason for clerical help.


    FOOTNOTES

* Corresponding author. Mailing address: National Hansen's Disease Programs, Laboratory Research Branch at Louisiana State University, P.O. Box 25072, Baton Rouge, LA 70894. Phone: (225) 346-5764. Fax: (225) 346-5786. E-mail: ladams1{at}lsu.edu.

Editor:   S. H. E. Kaufmann


    REFERENCES
Top
Abstract
Text
References

1. Adams, L. B., M. C. Dinauer, D. E. Morgenstern, and J. L. Krahenbuhl. 1997. Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice. Tubercle Lung Dis. 78:237-246[CrossRef][Medline].
2. Adams, L. B., S. G. Franzblau, Z. Vavrin, J. B. Hibbs, Jr., and J. L. Krahenbuhl. 1991. L-Arginine-dependent macrophage effector functions inhibit metabolic activity of Mycobacterium leprae. J. Immunol. 147:1642-1646[Abstract].
3. Adams, L. B., N. A. Soileau, J. R. Battista, and J. L. Krahenbuhl. 2000. Inhibition of metabolism and growth of Mycobacterium leprae by gamma-irradiation. Int. J. Lepr. 68:1-10.
4. Appelberg, R., and I. M. Orme. 1993. Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infection in murine macrophages. Immunology 80:352-359[Medline].
5. Bermudez, L. E. 1993. Differential mechanisms of intracellular killing of Mycobacterium avium and Listeria monocytogenes by activated human and murine macrophages. The role of nitric oxide. Clin. Exp. Immunol. 91:277-281[Medline].
6. Bogdan, C., M. Rollinghoff, and A. Diefenbach. 2000. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr. Opin. Immunol. 12:64-76[CrossRef][Medline].
7. Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B. R. Bloom. 1995. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63:736-740[Abstract].
8. Chan, J., Y. Xing, R. S. Magliozzo, and B. R. Bloom. 1992. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:1111-1122[Abstract/Free Full Text].
9. Chehl, S., J. Ruby, C. K. Job, and R. C. Hastings. 1983. The growth of Mycobacterium leprae in nude mice. Lepr. Rev. 54:283-304[Medline].
10. Colston, M. J., and G. R. Hilson. 1976. Growth of Mycobacterium leprae and M. marinum in congenitally athymic (nude) mice. Nature 262:736-741.
11. Denis, M. 1991. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell. Immunol. 132:150-157[CrossRef][Medline].
12. Ehlers, S., S. Kutsch, J. Benini, A. Cooper, C. Hahn, J. Gerdes, I. Orme, C. Martin, and E. T. Rietschel. 1999. NOS2-derived nitric oxide regulates the size, quantity and quality of granuloma formation in Mycobacterium avium-infected mice without affecting bacterial loads. Immunology 98:313-323[CrossRef][Medline].
13. Flynn, J. L., C. A. Scanga, K. E. Tanaka, and J. Chan. 1998. Effects of aminoguanidine on latent murine tuberculosis. J. Immunol. 160:1796-1803[Abstract/Free Full Text].
14. Gomes, M. S., M. Florido, T. F. Pais, and R. Appelberg. 1999. Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene. J. Immunol. 162:6734-6739[Abstract/Free Full Text].
15. Granger, D. L., J. B. Hibbs, Jr., and L. M. Broadnax. 1991. Urinary nitrate excretion in relation to murine macrophage activation. Influence of dietary L-arginine and oral NG-monomethyl-L-arginine. J. Immunol. 146:1294-1302[Abstract].
16. Laubach, V. E., E. G. Shesely, O. Smithies, and P. A. Sherman. 1995. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. USA 92:10688-10692[Abstract/Free Full Text].
17. MacMicking, J., Q. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323-350[CrossRef][Medline].
18. MacMicking, J. D., R. J. North, R. LaCourse, J. S. Mudgett, S. K. Shah, and C. F. Nathan. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. USA 94:5243-5248[Abstract/Free Full Text].
19. Ramasesh, N., L. B. Adams, S. G. Franzblau, and J. L. Krahenbuhl. 1991. Effects of activated macrophages on Mycobacterium leprae. Infect. Immun. 59:2864-2869[Abstract/Free Full Text].
20. Shepard, C. C., and D. H. McRae. 1968. A method for counting acid-fast bacteria. Int. J. Lepr. 36:78-82.
21. Weinberg, J. B. 1998. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol. Med. 4:557-591[Medline].


Infection and Immunity, September 2000, p. 5462-5465, Vol. 68, No. 9
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Hagge, D. A., Saunders, B. M., Ebenezer, G. J., Ray, N. A., Marks, V. T., Britton, W. J., Krahenbuhl, J. L., Adams, L. B. (2009). Lymphotoxin-{alpha} and TNF Have Essential but Independent Roles in the Evolution of the Granulomatous Response in Experimental Leprosy. Am. J. Pathol. 174: 1379-1389 [Abstract] [Full Text]  
  • Duthie, M. S., Reece, S. T., Lahiri, R., Goto, W., Raman, V. S., Kaplan, J., Ireton, G. C., Bertholet, S., Gillis, T. P., Krahenbuhl, J. L., Reed, S. G. (2007). Antigen-Specific Cellular and Humoral Responses Are Induced by Intradermal Mycobacterium leprae Infection of the Mouse Ear. Infect. Immun. 75: 5290-5297 [Abstract] [Full Text]  
  • Scollard, D. M., Adams, L. B., Gillis, T. P., Krahenbuhl, J. L., Truman, R. W., Williams, D. L. (2006). The Continuing Challenges of Leprosy. Clin. Microbiol. Rev. 19: 338-381 [Abstract] [Full Text]  
  • Lahiri, R., Randhawa, B., Krahenbuhl, J. (2005). Application of a viability-staining method for Mycobacterium leprae derived from the athymic (nu/nu) mouse foot pad. J Med Microbiol 54: 235-242 [Abstract] [Full Text]  
  • Tadesse, A., Shannon, E. J. (2005). Effects of Thalidomide on Intracellular Mycobacterium leprae in Normal and Activated Macrophages. CVI 12: 130-134 [Abstract] [Full Text]  
  • Hagge, D. A., Ray, N. A., Krahenbuhl, J. L., Adams, L. B. (2004). An In Vitro Model for the Lepromatous Leprosy Granuloma: Fate of Mycobacterium leprae from Target Macrophages after Interaction with Normal and Activated Effector Macrophages. J. Immunol. 172: 7771-7779 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adams, L. B.
Right arrow Articles by Krahenbuhl, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adams, L. B.
Right arrow Articles by Krahenbuhl, J. L.